VALUE-Dx

Antimicrobial resistance (AMR), as defined by the WHO, occurs when bacteria, viruses, fungi, and parasites no longer respond to medications. This is a growing global health crisis because AMR makes infections harder to treat and increases the risk of disease spread,

On 24 and 25 October 2019, the kick-off meeting for the VALUE-Dx ‘Clinical Studies’ work package was hosted at the Julius Centre of Health Sciences and Primary Care of the University Medical Center Utrecht in Zeist,

Antwerp (Belgium), London (UK), Marcy l’Etoile (France) – April 1, 2019

The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitrodiagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes.